SAMHD1 controls nucleoside-based cancer therapeutics, deoxyguanosine toxicity, and inflammationMichael D. Moore(University of Oxford), William James(University of Oxford)bioRxiv (Cold Spring Harbor Laboratory)August 27, 202210.1101/2022.08.25.505278Cited by 1SaveCiteExport RISWatch citationsRelated PapersEvidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera|Cell|2021|1.2kNeurological manifestations of dengue infection|The Lancet|2000|637Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera|Cell|2021|529A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy|mAbs|2020|35The nature and nurture of cell heterogeneity: accounting for macrophage gene-environment interactions with single-cell RNA-Seq|BMC Genomics|2017|25